Novavax's COVID-19 Vaccine Gets Back To Back Approval In Japan, Australia For Adolescents

Novavax's COVID-19 Vaccine Gets Back To Back Approval In Japan, Australia For Adolescents
  • Novavax Inc's NVAX Nuvaxovid (NVX-CoV2373) COVID-19 vaccine received expanded manufacturing and marketing approval in Japan for adolescents aged 12 through 17. 
  • Novavax has partnered with Takeda Pharmaceutical Co Ltd TAK to develop, manufacture, and distribute Nuvaxovid in Japan.
  • The Australian Therapeutic Goods Agency has granted expanded approval for provisional registration of Nuvaxovid for adolescents aged 12 through 17.
  • Also Read: Novavax's COVID-19 Vaccine For Adults Gets CDC Advisory Committee Recommendation.
  • The expanded approval was based on data from the ongoing pediatric expansion of PREVENT-19 Phase 3 trial. 
  • In the trial, Nuvaxovid achieved its primary effectiveness endpoint and demonstrated 80% overall clinical efficacy when the delta variant was the predominant circulating SARS-CoV-2 strain in the U.S.
  • Price Action: NVAX shares are down 0.58% at $55.19 during the market session on the last check Tuesday.
  • Photo by hakan german from Pixabay

Posted In: BriefsCOVID-19 CoronavirusCOVID-19 VaccineBiotechNewsHealth CareGeneral